Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

DOJ Tightens Oversight of DEI Programs: Implications for Rheumatology

From the College  |  August 10, 2025

On July 30, Attorney General Pam Bondi issued a memo titled Guidance for Recipients of Federal Funding Regarding Unlawful Discrimination to all federal agencies, clarifying how federal anti-discrimination laws apply to programs that might involve discriminatory practices, including those that fall under the umbrella of diversity, equity and inclusion (DEI).

Per the memo, recipients of federal funds must ensure that their programs do not discriminate on the basis of race, color, national origin, sex, religion or other protected traits, regardless of a program’s label, objectives or good intentions. The memo includes non-binding recommendations to help institutions comply, such as incorporating explicit nondiscrimination clauses into grant agreements, monitoring third-party compliance and terminating funding when necessary.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Here is how the memo may impact the practice of rheumatology.

Hiring, Promotion & Fellowship Selection

Academic rheumatology divisions that use race or sex as a factor in hiring, promotion or fellowship admissions may need to stop or rework those practices to avoid legal exposure. ACR members who are seeking employment at academic institutions that receive federal money should expect more conservative selection criteria and more sign-offs from human resources and legal departments.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Outreach Programs

Programs that were explicitly targeted by race or gender, such as medical school, residency and pre-med pipelines, could be restructured into broader socioeconomic or geographic outreach to keep diversity goals while reducing legal risk. That may slow diversification efforts in the short term unless programs are redesigned.

Clinical Trial Recruitment & Health Disparities Work

Grants and initiatives aimed at reducing disparities (e.g., recruitment of under-represented patients into trials, community engagement) may face additional scrutiny, especially if federal funding is involved. Projects should document medical/scientific justification for any targeted approaches.

Training, Curricula & Mandatory Education

Implicit-bias trainings or curricular elements that are perceived as having race or sex-based preferences could be challenged. Institutions will likely review or reframe trainings to emphasize evidence-based, universal patient-care benefits and avoid language that could be read as discriminatory.

Operational & Reputational Consequences

Expect increased legal/compliance reviews, potential chilling effects on voluntary DEI efforts and possible internal friction as faculty and leadership balance mission-driven equity work with risk avoidance. News coverage and public debate around this guidance may also affect faculty recruitment and fundraising.

Conclusion

The guidance does not outlaw efforts to improve access to care or to study health disparities. However, it raises the bar on how such efforts must be designed and documented when federal funds are involved. Rheumatology leaders should proactively review DEI programs, consult counsel and reframe activities where needed so the work to reduce inequities can continue in a legally defensible way. The ACR fervently believes in the high value that diversity brings to the rheumatology workforce and its ability to provide high-quality care for all.

The ACR will continue to actively monitor this development and respond as new details emerge on the policy’s implementation and potential impact on rheumatologists and their patients.

For further information about the ACR’s advocacy efforts, email the ACR’s advocacy team at [email protected]. ACR/ARP members can also schedule time to meet directly with the ACR’s advocacy team to discuss issues and challenges you are facing.

Key Takeaways

  • The Department of Justice (DOJ) has released guidance regarding diversity, equity and inclusion programs and the application of federal anti-discrimination laws to entities who receive federal funds.
  • The guidance emphasizes that entities receiving federal funds must ensure compliance with federal law and avoid discrimination based on protected characteristics, regardless of the program’s labels, objectives or intentions.
  • The guidance provides a non-exhaustive list of unlawful practices that could lead to the revocation of grant funding.
  • The guidance includes best practices to help entities that receive federal funds avoid violating the law.

Share: 

Filed under:Legal Updates Tagged with:Diversity

Related Articles
    melitas / shutterstock.com

    New ACR Subcommittee Will Advance Diversity, Equity & Inclusion

    October 13, 2021

    Diversity, equity and inclusion (DEI) are the focus of a new ACR/ARP subcommittee of the Collaborative Initiatives (COIN) Special Committee. The 13-member group will explore strategies to increase diversity in the rheumatology workforce pipeline and reduce implicit bias in such organizational processes as speaker recruitment and abstract review. “There is a new awareness at the…

    Gorodenkoff / shutterstock.com

    The NIAMS Diversity Supplement Program Offers Researcher Funding

    January 10, 2022

    The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is a component of the National Institutes of Health (NIH) that supports research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases, as well as the training of basic and clinical scientists to carry out this research. NIAMS recognizes the…

    New ACR Subcommittee Will Advance Diversity, Equity & Inclusion

    September 7, 2021

    The group’s goals include workforce diversification and inclusive speaker recruitment.

    G-Stock Studio / shutterstock.com

    Conquering Systemic Racism in Medicine

    October 19, 2020

    2020 has not only borne witness to a global pandemic, but also to increasing fervor in the fight for racial equity. In a wave of opposition to the systemic racism in the U.S., people have been in the streets demonstrating and protesting against social injustice and have taken to social media to promote political action….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences